Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19.
Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19.
复制标题
DOI：
10.3390/diagnostics12051164
复制
发表时间：
2022-05-07
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
白细胞介素 - 6（IL - 6）与多种危及生命的疾病进程相关。开发一种能够即时、准确检测IL - 6浓度的即时检验平台，可能会成为改善IL - 6介导疾病患者临床管理的宝贵工具。利用一个包含35名因新冠肺炎住院患者样本的现有生物样本库，一种新型量子磁传感平台被用于测定血浆IL - 6浓度。通过QDTI10x测量的IL - 6水平与Luminex检测法之间呈现出强相关性（r = 0.70，p值 < 0.001），QDTI80x与Luminex之间也是如此（r = 0.82，p值 < 0.001）。为了验证在IL - 6测量准确性方面QDTI不劣于Luminex，选取了两个临床参数：入住重症监护病房的需求和机械插管的需求。针对这些临床结果，对两种检测方法所测量的IL - 6浓度进行了比较。结果表明，两种检测方法的预测性能具有可比性，且相关系数显著。结论：简而言之，QDTI检测法有望作为一种潜在工具，用于IL - 6介导疾病患者的快速临床决策。它还可以降低医疗成本，并推动未来针对不同临床场景的各类生物分子即时检验的发展。
Interleukin-6 (IL-6) has been linked to several life-threatening disease processes. Developing a point-of-care testing platform for the immediate and accurate detection of IL-6 concentrations could present a valuable tool for improving clinical management in patients with IL-6-mediated diseases. Drawing on an available biobank of samples from 35 patients hospitalized with COVID-19, a novel quantum-magnetic sensing platform is used to determine plasma IL-6 concentrations. A strong correlation was observed between IL-6 levels measured by QDTI10x and the Luminex assay (r = 0.70, p-value < 0.001) and between QDTI80x and Luminex (r = 0.82, p-value < 0.001). To validate the non-inferiority of QDTI to Luminex in terms of the accuracy of IL-6 measurement, two clinical parameters—the need for intensive care unit admission and the need for mechanical intubation—were chosen. IL-6 concentrations measured by the two assays were compared with respect to these clinical outcomes. Results demonstrated a comparative predictive performance between the two assays with a significant correlation coefficient. Conclusion: In short, the QDTI assay holds promise for implementation as a potential tool for rapid clinical decision in patients with IL-6-mediated diseases. It could also reduce healthcare costs and enable the development of future various biomolecule point-of-care tests for different clinical scenarios.
登录
查看更多内容
影响因子：
4.6
作者：
Guillén L;Padilla S;Fernández M;Agulló V;García JA;Telenti G;García-Abellán J;Botella Á;Gutiérrez F;Masiá M
通讯作者：
Masiá M
影响因子：
2.5
作者：
Engel N;Krumeich A
通讯作者：
Krumeich A
影响因子：
2.7
作者：
Gong, Yan;Liang, Shaocong;Yuan, Xiaopeng
通讯作者：
Yuan, Xiaopeng
影响因子：
--
作者：
Colombo, Christopher J;Colombo, Rhonda E;Liang, C Jason
通讯作者：
Liang, C Jason
中国急诊科对可疑患者的经验和BNP POCT平台的使用。
影响因子：
1.7
作者：
Qihong G;Zhixin W;Mingfeng H;Lianhong Y;Wenchong X
通讯作者：
Wenchong X